Bio-Rad to Invest in Oncocyte for Exclusive Global Transplant Monitoring Technology, Eyeing FDA Clearance and Market Expansion

Bio-Rad expects to make equity investment in support of deal - Agreement provides for global exclusivity in transplant monitoring commercialization - Bio-R...

April 12, 2024 | Friday | News
Denovo Biopharma's Liafensine Shows Promise in Phase 2b Trial for Treatment-Resistant Depression

Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative drugs, today announced positive results for its bi...

April 09, 2024 | Tuesday | News
OM1 and Medtronic Collaborate on Study Demonstrating Reduced Healthcare Resource Use with PROPEL Devices in Sinus Surgery

-OM1, the leading AI and insights-driven technology and data company specializing in personalized medicine, evidence generation, and real-world evidence, t...

April 09, 2024 | Tuesday | News
GE HealthCare Introduces Caption AI for Vscan Air SL Ultrasound System, Enhancing Cardiac Care Accessibility

GE HealthCare (Nasdaq: GEHC) announces a groundbreaking advancement in cardiac care with the launch of Caption AI artificial intelligence (AI)-driven softw...

April 04, 2024 | Thursday | News
EnteroBiotix Completes £27 Million Funding Round to Advance Microbiome Therapeutics for Gut Disorders

EnteroBiotix Limited, a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome therapeutics,  announced th...

April 04, 2024 | Thursday | News
dsm-firmenich and OMG Pharma Collaborate on CBD-Based Insomnia Drugs

Leveraging dsm-firmenich’s high quality GMP CBD active pharmaceutical ingredient (API) and leading-edge formulation capabilities, chiefly its bioavai...

April 03, 2024 | Wednesday | News
Bristol Myers Squibb’s Reblozyl® Receives Expanded EU Approval for LR-MDS Treatment

  Bristol Myers Squibb (NYSE: BMY) has announced the European Commission's (EC) expanded approval of Reblozyl® (luspatercept) for the first-line ...

April 03, 2024 | Wednesday | News
Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders

  Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company specializing in allosteric modulation-based drug development,...

April 03, 2024 | Wednesday | News
Voydeya Approved as Add-On Therapy for Rare PNH Treatment in the US

Voydeya (danicopan) has been granted approval in the United States as an add-on therapy for the treatment of extravascular haemolysis (EVH) in adults diagn...

April 02, 2024 | Tuesday | News
Incyte and CMS Announce Collaboration and License Agreement for Povorcitinib, an Oral JAK1 Inhibitor, in Mainland China, Hong Kong, Macau, Taiwan and Southeast Asia

Incyte and China Medical System Holdings Limited  are pleased to announce that on March 31, 2024, Incyte and CMS, through a wholly-owned dermatology m...

April 02, 2024 | Tuesday | News
Function Oncology and Volastra Therapeutics Form Strategic Partnership to Enhance Precision Cancer Treatment

-Function Oncology, a company transforming the operating system of precision medicine with CRISPR-powered platform technology, today announced an innovativ...

March 27, 2024 | Wednesday | News
FDA Approves Roche's First Molecular Test for Malaria Screening in Blood Donors

The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria Malaria is a serious and potentially fatal paras...

March 27, 2024 | Wednesday | News
Johnson & Johnson Announces FDA Approval of OPSYNVI® as First Once-Daily Single-Tablet Combo Therapy for Pulmonary Arterial Hypertension (PAH)

   Johnson & Johnson has announced the approval of OPSYNVI® by the U.S. Food and Drug Administration (FDA), marking a significant advanc...

March 25, 2024 | Monday | News
New Treatment Option for Prostate Cancer Shows Successful Outcomes

    Prostate cancer treatment traditionally involves radiation or surgery, both carrying risks of adverse effects like urinary incontinence and...

March 25, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close